SavedAdd your journal

Journals / Cukurova Medical Journal / 2019 / Cilt: 44 - Sayı: 3

Serum apelin-36 levels in pre-diabetics and newly diagnosed diabetes mellitus patients

Pre-diyabetik ve yeni tanı almış tip 2 diyabetli hastalarda serum apelin-36 düzeyleri

Zeynep Mine YALÇINKAYA KARA
Erdinç SERİN
İsmail DAĞ
Özden SERİN
Pages
1094–1101
Publication Date
2019-09-30
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Other parameters analyzed for glucose metabolism and cardiovascular risk factors such as fasting glucose, HbA1c, HOMA-IR, fibrinogen, insulin, cortisol, C-peptide, LDL-cholesterol, HDL-cholesterol, VLDL-cholesterol, triglycerides, total cholesterol were significantly higher in the study groups when compared to the control group.Conclusion: In the future serum apelin-36 levels can be used as an indicator for presenting the insulin resistance and impairment in glucose metabolism in the early periods.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Purpose: The aim of this study was to investigate the levels of parameters for glucose metabolism and cardiovascular risk factors and apelin-36 in patients grouped as having impaired fasting glucose(IFG), IFG and impaired glucose tolerance(IGT), newly diagnosed type 2 DM and the control group.Materials and Methods: Fifty-three women and twenty-seven men, totally eighty subjects were enrolled in this study.
📊
Key Findings & Data:Group1: Normoglycemic controls(n:20), Group2: subjects with IFG(n:20), Group3: combined IFG subjects which included both IFG and IGT patients(n:20), Group4: Newly diagnosed type 2 DM patients(n:20).
💡
Conclusion & Impact:Other parameters analyzed for glucose metabolism and cardiovascular risk factors such as fasting glucose, HbA1c, HOMA-IR, fibrinogen, insulin, cortisol, C-peptide, LDL-cholesterol, HDL-cholesterol, VLDL-cholesterol, triglycerides, total cholesterol were significantly higher in the study groups when compared to the control group.Conclusion: In the future serum apelin-36 levels can be used as an indicator for presenting the insulin resistance and impairment in glucose metabolism in the early periods.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:apelin 36 · pre-diabet · diabet

Abstract

Purpose: The aim of this study was to investigate the levels of parameters for glucose metabolism and cardiovascular risk factors and apelin-36 in patients grouped as having impaired fasting glucose(IFG), IFG and impaired glucose tolerance(IGT), newly diagnosed type 2 DM and the control group.Materials and Methods: Fifty-three women and twenty-seven men, totally eighty subjects were enrolled in this study. The patients were classified into four groups according to their oral glucose tolerance test (OGTT) results. Group1: Normoglycemic controls(n:20), Group2: subjects with IFG(n:20), Group3: combined IFG subjects which included both IFG and IGT patients(n:20), Group4: Newly diagnosed type 2 DM patients(n:20). Levels of glucose, lipids, HbA1c, fibrinogen, insulin, cortisol, serum apelin-36 and C-peptide were analyzed.Results: There was a statistically significant difference regarding the levels of apelin-36 between group 1 and the study groups 2, 3 and 4, respectively. Other parameters analyzed for glucose metabolism and cardiovascular risk factors such as fasting glucose, HbA1c, HOMA-IR, fibrinogen, insulin, cortisol, C-peptide, LDL-cholesterol, HDL-cholesterol, VLDL-cholesterol, triglycerides, total cholesterol were significantly higher in the study groups when compared to the control group.Conclusion: In the future serum apelin-36 levels can be used as an indicator for presenting the insulin resistance and impairment in glucose metabolism in the early periods.

Özet

Amaç: Bu çalışmada, açlık glukozu (IFG), bozulmuş glukoz toleransı (IGT) ve yeni tanı almış tip 2 DM olarak gruplandırılmış hastalarda; glukoz metabolizması ve kardiyovasküler risk faktörleri parametreleri ve apelin-36 düzeylerini araştırılması amaçlanmıştır..Gereç ve Yöntem: Elli üç kadın ve yirmi yedi erkek, toplam seksen katılımcı bu çalışmaya dahil edildi. Orak glükoz tolerans testi (OGTT) sonuçlarına göre hastalar dört gruba ayrıldı. Grup 1: Normoglisemik kontroller (n: 20), Grup2: IFG'li hastalar (n: 20), Grup3: IFG ve IGT'li hastalar (n: 20), Grup4: Yeni tanı almış tip 2 DM hastaları (n: 20). Glikoz, lipidler, HbA1c, fibrinojen, insülin, kortizol, C-peptid ve Apelin-36 seviyeleri analiz edildi.Bulgular: Apelin-36 düzeylerinde grup 1 ile çalışma grupları 2,3 ve 4 arasında istatistiksel olarak anlamlı bir fark vardı). Glukoz metabolizması ve kardiyovasküler risk faktörleri için analiz edilen açlık glukozu, HbA1c, HOMA-IR, fibrinojen, insülin, kortizol, C-peptid, LDL-kolesterol, HDL-kolesterol, VLDL-kolesteroll, triglisterit, total kolesterol gibi parametreler çalışma grubu ile kontrol grubu karşılaştırıldığında anlamlı bir fark bulunduSonuç: Gelecekte serum apelin-36 düzeylerinin erken dönemlerde glukoz metabolizma bozukluğunu ve insülin direncini göstermek için bir belirteç olarak kullanılabileceğini düşünüyoruz.

🔖

Cite This Article

KARA, Z. M. Y., SERİN, E., DAĞ, İ., SERİN, Ö. (2019). Serum apelin-36 levels in pre-diabetics and newly diagnosed diabetes mellitus patients. Cukurova Medical Journal, Cilt: 44 - Sayı: 3, 1094–1101. https://ajindex.com/articles/56408

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. American Diabetes Association. Standards of medical care in diabetes - 2012. Diabetes Care. 2012;35:11–63
  2. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome. Circulation.2005;112:2735-52
  3. Kovanen PT, Pentikainen MO. Decorin links lowdensity lipoproteins (LDL) to collagen: a novel mechanism for retention of LDL in the atherosclerotic plaque. Trends Cardiovasc Med. 1999;9:86-91
  4. Altunkaynak BZ, Özbek E. Yağ dokusu endokrin bir organ mıdır? Dicle Tıp Dergisi. 2005;32:211-7
  5. Gimble JM. Adipose tissue-derived therapeutics. Expert opinion on biological therapy. 2003;3:705-13
  6. Tatemoto K, Takayama K, Zou M-X, Kumaki I, Zhang W, Kumano K et al. The novel peptide apelin lowers blood pressure via a nitric oxide-dependent mechanism. Regul Pept. 2001;99:87-92
  7. O'Dowd BF, Heiber M, Chan A, Heng HH, Tsui LC, Kennedy JL et al. A human gene that shows identity with the gene encoding the angiotensin receptor is located on chromosome 11. Gene. 1993;136:355-60
  8. Tatemoto K, Hosoya M, Habata Y, Fujii R, Kakegawa T, Zou MX et al. Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor. Biochem Biophys Res Commun. 1998;251:471-6
  9. Lee DK, Cheng R, Nguyen T,Fan T, Kariyawasam AP, Liu Y et al. Characterization of apelin, the ligand for the APJ receptor. J Neurochem. 2000;74:34-41
  10. Bełtowski J. Apelin and visfatin: unique "beneficial" adipokines upregulated in obesity? Med Sci Monit Basic Res. 2006;12:RA112-9
  11. Llorens-Cortès C, Beaudet A. Apelin, a neuropeptide that counteracts vasopressin secretion. Med Sci. 2005;21:741–6
  12. Baranova A, Randhawa M, Jarrar M, Younossi ZM. Adipokines and melanocortins in the hepatic manifestation of metabolic syndrome: nonalcoholic fatty liver disease. Expert Rev Mol Diagn. 2007;7:195- 205
  13. Medhurst AD, Jennings CA, Robbins MJ,Davis RP, Ellis C, Winborn KY et al. Pharmacological and immunohistochemical characterization of the APJ receptor and its endogenous ligand apelin. J Neurochem. 2003;84:1162-72
  14. Boucher J, Masri B, Daviaud D, Gesta S, Guigné C, Mazzucotelli A et al. Apelin, a newly identified adipokine up-regulated by insulin and obesity. Endocrinology. 2005;146:1764-71
  15. Winzell MS, Magnusson C, Ahrén B. The apj receptor is expressed in pancreatic islets and its ligand, apelin, inhibits insulin secretion in mice. Regul Pept. 2005;131:12-7
  16. Jin W, Su X, Xu M, Liu Y, Shi J, Lu L